Novavax included in University of Oxford Com-COV3 study comparing mixed COVID-19 vaccine in adolescents
On Sept. 16, 2021, Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing…
Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…
Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
NIH launched clinical trial of universal influenza vaccine candidate
On Jun. 1, 2021, a first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle…
The Priestley Medal was awarded to Paul Alivisatos
On Apr. 9, 2021, the American Chemical Society awarded The Priestley Medal to Paul Alivisatos “to recognize distinguished…
Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccines
On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…
Baxter Biopharma Solutions announced sterile manufacturing agreement for Novavax COVID-19 vaccine
On Jan. 11, 2021, Baxter announced an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax COVID-19 recombinant…
NIH neuroscientists isolated promising mini antibodies against COVID-19 from a llama
On Dec. 22, 2020, the NIH researchers announced they had isolated a set of promising, tiny antibodies, or…
Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir
On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…
Novavax provided phase 3 COVID-19 vaccine clinical development update
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivity
On Sept. 25, 2020, scientists from the University of Oxfordï¾’s Nuffield Department of Medicine published their evaluation of…
NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19
On Sept. 16, 2020, NanoViricides announced that it had nominated a clinical drug candidate for the treatment of…
Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of India
On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India which…
Novavax initiated phase 2 portion of phase 1/2 clinical trial of COVID-19 vaccine
On Aug. 24, 2020, Novavax announced that the first volunteers were enrolled in the Phase 2 portion of…
Novavax initiated efficacy trial of COVID-19 vaccine in South Africa
On Aug. 17, 2020, Novavax announced the beginning of a Phase 2b clinical trial in South Africa to…
Novavax and UK Government announced collaboration and purchase agreement for Novavax’ COVID-19 vaccine candidate
On Aug. 14, 2020, Novavax announced it had signed a Heads of Terms (Term Sheet) with the Government…
Novavax and SK bioscience announced collaboration for Novavax COVID-19 vaccine candidate
On Aug. 13, 2020, Novavax and SK bioscience announced a development and supply agreement for the antigen component…
Scientists revealed structural details of spike protein used in leading COVID-19 vaccine
On Aug. 7, 2020, scientists at Scripps Research announced they had obtained high-resolution, atomic-scale details of the structure…
Biotechnology | COVID-19 | Infectious Disease | Life Science News | Nanotechnology | Pharmaceutical | Vaccine
Novavax and Takeda announced collaboration for Novavax COVID-19 vaccine candidate in Japan
On Aug. 7, 2020, Novavax and Takeda Pharmaceutical announced a partnership for the development, manufacturing and commercialization of…
Biotechnology | COVID-19 | Infectious Disease | Life Science News | Nanotechnology | Therapeutics | Vaccine
Novavax signed COVID-19 vaccine supply deal with India’s Serum Institute
On Aug. 6, 2020, Novavax announced it had entered a supply and license agreement with the Serum Institute…
Novavax announced positive phase 1 data for its COVID-19 vaccine candidate
On Aug. 4, 2020, Novavax announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of…
Serum Institute of India received approval to start human trials for Oxford vaccine
On Aug. 1, 2020, Novavax announced it had received approval to start human trials in India for the…
Novavax and FUJIFILM Diosynth Biotechnologies initiated large scale manufacturing of COVID-19 vaccine candidate
On Jul. 23, 2020, Novavax and FUJIFILM Diosynth Biotechnologies announced an agreement to manufacture bulk drug substance for…
HDT BIOï¾’s COVID-19 vaccine candidate HDT-301 induced neutralizing antibody responses after single injection
On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they…
Engineered llama antibodies neutralised Covid-19 virus
On Jul. 13, 2020, a team of researchers from Oxford University, the Rosalind Franklin Institute, Diamond Light Source…
NanoViricides reported safety and tolerability of anti-Coronavirus drug candidates observed in animal model
On Jul. 8, 2020, NanoViricides announced that excellent safety and tolerability of the drug candidates it is developing…
Novavax announced $1.6 billion funding from Operation Warp Speed
On Jul. 7, 2020, Novavax announced that it had been selected to participate in Operation Warp Speed, a…